Arnold, L. Eugene
Roy, Arunima
Taylor, Eric
Hechtman, Lily
Sibley, Margaret
Swanson, James M.
Mitchell, John T.
Molina, Brooke S. G.
Rohde, Luis A.
Funding for this research was provided by:
National Institute of Mental Health
National Institute on Drug Abuse
Article History
Received: 20 March 2018
Accepted: 3 September 2018
First Online: 19 September 2018
Compliance with ethical standards
:
: Dr. Arnold has received research funding from Forest, Lilly, Noven, Shire, Supernus, Roche, and YoungLiving, consulted with Pfizer, Tris Pharma, and Waypoint, and been on advisory boards for Arbor, Ironshore, Otsuka, Pfizer, Roche, Seaside Therapeutics, and Shire. Dr. Taylor has consulted for South London and Maudsley NHS Foundation Trust and received book royalties from Wiley Blackwell and Oxford University Press. Dr. Hechtman has received research support, served on advisory boards, and been a speaker for Lilly, GlaxoSmithKline, Ortho-Janssen, Purdue, Shire, and Ironshore, and received book royalties from Guilford, APA, John Hopkins, and Oxford University Press. Dr. Sibley receives royalties from Guilford Press. Dr. Swanson received support years from NLS Pharma and Medice expert board meetings. Dr. Mitchell received royalties from New Harbinger Press. Dr. Rohde was on speakers’ bureau and/or consulted for Eli-Lilly, Janssen-Cilag, Medice, Novartis and Shire, and received royalties from Oxford Press and ArtMed and travel awards to 2015 WFADHD and 2016 AACAP; Outpatient Programs chaired by him received unrestricted educational/research support from: Eli-Lilly, Janssen-Cilag, Novartis, and Shire. Dr. Molina and Dr. Roy have no disclosures.